Wedbush Upgrades Harpoon Therapeutics (HARP) to Outperform

Wedbush analyst Robert Driscoll upgraded Harpoon Therapeutics (NASDAQ: HARP) from Neutral to Outperform with a price target of $7.00 (from $5.00).

For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.

Shares of Harpoon Therapeutics closed at $2.00 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Sumco Corp (3436:JP) (SUOPY) to Equalweight
• HSBC Assumes U.S. Bancorp (USB) at Buy
• Xenon Pharmaceuticals (XENE) PT Lowered to $90 at Jefferies